Cargando…
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416952/ https://www.ncbi.nlm.nih.gov/pubmed/30867071 http://dx.doi.org/10.1186/s40425-019-0557-5 |
_version_ | 1783403463392100352 |
---|---|
author | Bergerot, Cristiane Decat Bergerot, Paulo Gustavo Philip, Errol J. Hsu, Jo Ann Dizman, Nazli Vaishampayan, Ulka Dorff, Tanya Pal, Sumanta Kumar |
author_facet | Bergerot, Cristiane Decat Bergerot, Paulo Gustavo Philip, Errol J. Hsu, Jo Ann Dizman, Nazli Vaishampayan, Ulka Dorff, Tanya Pal, Sumanta Kumar |
author_sort | Bergerot, Cristiane Decat |
collection | PubMed |
description | BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients with advanced GU cancers initiating immunotherapy and quality of life (QOL), anxiety and depression. PATIENT AND METHODS: A single-institution, cross-sectional survey study was conducted with patients preparing to receive CPIs for treatment of metastatic renal cell carcinoma (RCC), urothelial cancer (UC) and prostate cancer (PC). Patients were assessed prior to initiation of immunotherapy for expectations of cure (divided into four quartiles), quality of life (QOL; Functional Assessment of Chronic Illness Therapy-General [FACT-G]), and symptoms of anxiety and depression (PROMIS). RESULTS: Sixty patients were enrolled, with metastatic RCC, UC and PC comprising 63, 28 and 8% of the study population, respectively. Median age of the cohort was 65 (range, 31–91), and 68% were male; 33% received CPI in the first-line setting. Despite extensive counseling from oncologists regarding potential clinical outcomes with immunotherapy, a substantial proportion of patients (23%) harbored inaccurate expectations regarding the potential benefit of immunotherapy. Importantly, patients with accurate expectations of cure reported lower anxiety scores using the PROMIS-Anxiety inventory. No significant differences were found between expectations of cure and quality of life or depression, using the FACT-G and PROMIS-Depression inventories, respectively. CONCLUSION: The current study found that a considerable proportion of patients with advanced GU cancers harbor inaccurate expectations concerning the potential benefit of immunotherapy. These results suggest that more effective counselling may mitigate patient anxiety, and potentially promote treatment satisfaction and adherence. |
format | Online Article Text |
id | pubmed-6416952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64169522019-03-25 Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy Bergerot, Cristiane Decat Bergerot, Paulo Gustavo Philip, Errol J. Hsu, Jo Ann Dizman, Nazli Vaishampayan, Ulka Dorff, Tanya Pal, Sumanta Kumar J Immunother Cancer Short Report BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients with advanced GU cancers initiating immunotherapy and quality of life (QOL), anxiety and depression. PATIENT AND METHODS: A single-institution, cross-sectional survey study was conducted with patients preparing to receive CPIs for treatment of metastatic renal cell carcinoma (RCC), urothelial cancer (UC) and prostate cancer (PC). Patients were assessed prior to initiation of immunotherapy for expectations of cure (divided into four quartiles), quality of life (QOL; Functional Assessment of Chronic Illness Therapy-General [FACT-G]), and symptoms of anxiety and depression (PROMIS). RESULTS: Sixty patients were enrolled, with metastatic RCC, UC and PC comprising 63, 28 and 8% of the study population, respectively. Median age of the cohort was 65 (range, 31–91), and 68% were male; 33% received CPI in the first-line setting. Despite extensive counseling from oncologists regarding potential clinical outcomes with immunotherapy, a substantial proportion of patients (23%) harbored inaccurate expectations regarding the potential benefit of immunotherapy. Importantly, patients with accurate expectations of cure reported lower anxiety scores using the PROMIS-Anxiety inventory. No significant differences were found between expectations of cure and quality of life or depression, using the FACT-G and PROMIS-Depression inventories, respectively. CONCLUSION: The current study found that a considerable proportion of patients with advanced GU cancers harbor inaccurate expectations concerning the potential benefit of immunotherapy. These results suggest that more effective counselling may mitigate patient anxiety, and potentially promote treatment satisfaction and adherence. BioMed Central 2019-03-12 /pmc/articles/PMC6416952/ /pubmed/30867071 http://dx.doi.org/10.1186/s40425-019-0557-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Bergerot, Cristiane Decat Bergerot, Paulo Gustavo Philip, Errol J. Hsu, Jo Ann Dizman, Nazli Vaishampayan, Ulka Dorff, Tanya Pal, Sumanta Kumar Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title | Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title_full | Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title_fullStr | Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title_full_unstemmed | Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title_short | Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
title_sort | perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416952/ https://www.ncbi.nlm.nih.gov/pubmed/30867071 http://dx.doi.org/10.1186/s40425-019-0557-5 |
work_keys_str_mv | AT bergerotcristianedecat perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT bergerotpaulogustavo perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT philiperrolj perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT hsujoann perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT dizmannazli perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT vaishampayanulka perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT dorfftanya perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy AT palsumantakumar perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy |